GANCICLOVIR SUSCEPTIBILITIES OF CYTOMEGALOVIRUS (CMV) ISOLATES FROM SOLID-ORGAN TRANSPLANT RECIPIENTS WITH CMV VIREMIA AFTER ANTIVIRAL PROPHYLAXIS

被引:57
作者
BOIVIN, G
ERICE, A
CRANE, DD
DUNN, DL
BALFOUR, HH
机构
[1] UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,BOX 437 UMHC,15-144 PHILLIPS WANGENSTEEN BLDG,MINNEAPOLIS,MN 55455
[2] UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455
[3] UNIV MINNESOTA,SCH MED,DEPT SURG,MINNEAPOLIS,MN 55455
[4] UNIV MINNESOTA,SCH MED,DEPT PAEDIAT,MINNEAPOLIS,MN 55455
关键词
D O I
10.1093/infdis/168.2.332
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ganciclovir susceptibility studies were done on the last cytomegalovirus (CMV) isolate available from 42 solid organ transplant recipients with CMV viremia who were enrolled in a prospective CMV prophylactic trial. Viruses were categorized as follows: 13 isolates (group 1) from patients who received ganciclovir prophylaxis; 9 isolates (group 2) from patients who received acyclovir prophylaxis; 8 isolates (group 3) from patients who received acyclovir prophylaxis and ganciclovir treatment; and 12 isolates (group 4) from patients who received prophylaxis and treatment with ganciclovir. All CMV isolates were sensitive to ganciclovir (mean 50% inhibitory concentration [IC50] = 1.7 muM; range, 0.2-5.3 muM). Mean IC50 values (in muM) were 1.7 for group 1 isolates, 1.2 for group 2 isolates, 2.2 for group 3 isolates, and 1.7 for group 4 isolates (P > .05). Thus, acyclovir or ganciclovir prophylaxis in solid organ transplant patients did not select ganciclovir-resistant isolates of CMV.
引用
收藏
页码:332 / 335
页数:4
相关论文
共 13 条
[1]   FAILURE OF PROPHYLACTIC GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF LUNG TRANSPLANTS [J].
BAILEY, TC ;
TRULOCK, EP ;
ETTINGER, NA ;
STORCH, GA ;
COOPER, JD ;
POWDERLY, WG .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (03) :548-552
[2]   A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR FOR THE PREVENTION OF CYTOMEGALO-VIRUS DISEASE IN RECIPIENTS OF RENAL-ALLOGRAFTS [J].
BALFOUR, HH ;
CHACE, BA ;
STAPLETON, JT ;
SIMMONS, RL ;
FRYD, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (21) :1381-1387
[3]  
BALFOUR HH, 1990, REV INFECT DIS, V12, pS849
[4]   RAPID ANTIVIRAL DNA-DNA HYBRIDIZATION ASSAY FOR HUMAN CYTOMEGALOVIRUS [J].
DANKNER, WM ;
SCHOLL, D ;
STANAT, SC ;
MARTIN, M ;
SONKE, RL ;
SPECTOR, SA .
JOURNAL OF VIROLOGICAL METHODS, 1990, 28 (03) :293-298
[5]   PREVALENCE OF RESISTANCE IN PATIENTS RECEIVING GANCICLOVIR FOR SERIOUS CYTOMEGALOVIRUS-INFECTION [J].
DREW, WL ;
MINER, RC ;
BUSCH, DF ;
FOLLANSBEE, SE ;
GULLETT, J ;
MEHALKO, SG ;
GORDON, SM ;
OWEN, WF ;
MATTHEWS, TR ;
BUHLES, WC ;
DEARMOND, B .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (04) :716-719
[6]   PROGRESSIVE DISEASE DUE TO GANCICLOVIR-RESISTANT CYTOMEGALO-VIRUS IN IMMUNOCOMPROMISED PATIENTS [J].
ERICE, A ;
CHOU, S ;
BIRON, KK ;
STANAT, SC ;
BALFOUR, HH ;
JORDAN, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (05) :289-293
[7]   PHARMACOLOGICAL BASIS FOR HIGH-DOSE ORAL ACYCLOVIR PROPHYLAXIS OF CYTOMEGALOVIRUS DISEASE IN RENAL-ALLOGRAFT RECIPIENTS [J].
FLETCHER, CV ;
ENGLUND, JA ;
EDELMAN, CK ;
GROSS, CR ;
DUNN, DL ;
BALFOUR, HH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (05) :938-943
[8]   EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
GOODRICH, JM ;
MORI, M ;
GLEAVES, CA ;
DUMOND, C ;
CAYS, M ;
EBELING, DF ;
BUHLES, WC ;
DEARMOND, B ;
MEYERS, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) :1601-1607
[9]   CYTOMEGALOVIRUS ISOLATE RESISTANT TO GANCICLOVIR AND FOSCARNET FROM A MARROW TRANSPLANT PATIENT [J].
KNOX, KK ;
DROBYSKI, WR ;
CARRIGAN, DR .
LANCET, 1991, 337 (8752) :1292-1293
[10]   A CONTROLLED TRIAL OF GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER HEART-TRANSPLANTATION [J].
MERIGAN, TC ;
RENLUND, DG ;
KEAY, S ;
BRISTOW, MR ;
STARNES, V ;
OCONNELL, JB ;
RESTA, S ;
DUNN, D ;
GAMBERG, P ;
RATKOVEC, RM ;
RICHENBACHER, WE ;
MILLAR, RC ;
DUMOND, C ;
DEAMOND, B ;
SULLIVAN, V ;
CHENEY, T ;
BUHLES, W ;
STINSON, EB .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (18) :1182-1186